Historically, hepatitis A virus (HAV) has been highly prevalent in developing countries, with most infections occurring during childhood, when they are likely to be asymptomatic. Shifts in the acquisition of infection from childhood to adulthood, when clinical hepatitis is more likely, may leave populations vulnerable to large outbreaks. We conducted cross-sectional serosurveys from 1995 to 2008 in four Pacific Island nations to determine the proportion of people previously infected with HAV by measuring antibodies to HAV (anti-HAV). In American Samoa, 0.0% of 4- to 6-year-olds (95% CI 0.0-3.7) were anti-HAV positive. In Chuuk, FSM, 8.6% of 2- to 6-year-olds (95% CI 5.7-11.5) were anti-HAV positive compared with 98.3% of individuals > or =16 years old (95% CI 96.6-100). In Pohnpei, FSM, 0.8% of 2- to 9-year-olds (95% CI 0.0-1.6) were anti-HAV positive compared with 95.1% of > or =16 year-olds (95% CI 92.2-98.0). In RMI, 85.7% (95% CI 81.9-89.5) of 4- to 9-year-olds were anti-HAV positive. In Palau, 0.7% of 7- to 8-year-olds were anti-HAV positive (95% CI 0.0-1.8). The low HAV seroprevalence among children in American Samoa, FSM and Palau may indicate a vulnerability to hepatitis A morbidity among these populations. These data will be useful for evaluating the need for hepatitis A surveillance and vaccination programs.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.trstmh.2009.05.001DOI Listing

Publication Analysis

Top Keywords

anti-hav positive
20
hepatitis virus
8
pacific island
8
island nations
8
american samoa
8
6-year-olds 95%
8
positive compared
8
95%
7
anti-hav
6
positive
5

Similar Publications

Background: Hepatitis A infections continue to be a major global public health problem. The epidemiology and seroprevalence of hepatitis A virus (HAV) have important public health implications. This study aimed to retrospectively examine the hepatitis A cases and hepatitis A seroprevalence in our region in our hospital with the highest number of inpatient and outpatient cases in Istanbul.

View Article and Find Full Text PDF

Background: Viral hepatitis is a disease that is more prevalent among individuals residing in remote regions and in contexts of social vulnerability. The objective of this study was to ascertain the seroprevalence of hepatitis A (HAV), B (HBV), and C (HCV) in vulnerable communities in the rural area of São João do Piauí (SJP), northern Brazil.

Methods: Immunoenzymatic assays were employed to detect the presence of anti-HAV (total and IgM), HBsAg, anti-HBc, anti-HBs, and anti-HCV serological markers in serum samples.

View Article and Find Full Text PDF

Exploring hepatitis A dynamics in Israel, 2019-2022.

Sci Total Environ

December 2024

Central Virology Laboratory, Ministry of Health, Israel; Faculty of Medicine, Tel-Aviv University, Israel.

Article Synopsis
  • Continuous monitoring of Hepatitis A Virus (HAV) in Israel revealed that between 2019 and 2022, there were 158 reported cases and 12.9% of sewage samples tested positive for HAV RNA, with a notable peak in 2019.
  • The COVID-19 pandemic led to a decrease in HAV cases and positive sewage samples during 2020, likely due to lockdown measures affecting virus transmission.
  • The predominant sub-genotype identified was IB, with small clusters of transmission among various community groups, emphasizing the need for combined clinical and environmental tracking for effective HAV management and vaccination efforts targeting at-risk adults.
View Article and Find Full Text PDF
Article Synopsis
  • Hepatitis A virus (HAV) infection is a major cause of viral hepatitis globally, and in Italy, the anti-HAV vaccine is currently only given to specific high-risk groups, not through a universal program.
  • A study analyzed HAV immunity levels in patients aged 0-95 at a hospital in Salerno, Italy, over 9 years, finding high seroprevalence overall but a significant decrease during the pandemic years compared to the pre-pandemic period.
  • Male patients had a higher seroprevalence than females, especially in the 61-70 age group, suggesting that ongoing monitoring and possibly a universal vaccination program is needed to improve immunity and reduce HAV incidence.
View Article and Find Full Text PDF

In 2023, passive laboratory-based surveillance showed an increase in hepatitis A virus (HAV) infection. We investigated hepatitis A incidence using the notifiable medical condition surveillance system (NMCSS) data and molecularly characterised positive blood samples from the Western Cape province for 2023. All HAV IgM seropositive cases from the NMCSS from 1 January to 31 October 2023 in South Africa were investigated.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!